Juxtaglomerular apparatus hyperplasia under dual angiotensin blockade. A footprint of adequate RAS inhibition or a concern for renal fibrosis?

BMC Nephrology

Volumn 13, Issue 1, 2012, Pages

  Fernandez Fernandez, Beatriz ^a   Ortiz, Alberto ^a   Gomez Guerrero, Carmen ^a   Barat, Antonio ^b   Martín Cleary, Catalina ^a   Egido, Jesús ^a,c  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b Pathology Division   (Spain)

^c 28400 Madrid   (Spain)

Author keywords

Angiotensin; Juxtaglomerular apparatus hyperplasia; Nephrotic syndrome; Paricalcitol; Renin

Indexed keywords

ANTIHYPERTENSIVE AGENT; CANDESARTAN PLUS HYDROCHLOROTHIAZIDE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; QUINAPRIL; RENIN; RITUXIMAB; TACROLIMUS; UNCLASSIFIED DRUG; VALSARTAN;

ADULT; ARTICLE; CASE REPORT; CLINICAL EXAMINATION; DRUG DOSE REDUCTION; GLOMERULOPATHY; HUMAN; HUMAN TISSUE; HYPERTENSION; JUXTAGLOMERULAR APPARATUS; JUXTAGLOMERULAR APPARATUS HYPERPLASIA; KIDNEY BIOPSY; KIDNEY FIBROSIS; LABORATORY TEST; MALE; MULTIPLE CYCLE TREATMENT; NEPHROTIC SYNDROME; PROTEIN EXPRESSION; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; HUMANS; HYPERPLASIA; JUXTAGLOMERULAR APPARATUS; MALE; NEPHROTIC SYNDROME; RENIN; RENIN-ANGIOTENSIN SYSTEM; YOUNG ADULT;

EID: 84860146520     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-13-21     Document Type: Article

References (21)

1. Dual RAAS blockade is desirable in kidney disease: con. Bakris GL, Kidney Int 2010 78 546 549 10.1038/ki.2010.226 20664560
2. Have we fallen off target with concerns surrounding dual RAAS blockade? Lattanzio MR, Weir MR, Kidney Int 2010 78 539 545 10.1038/ki.2010.225 20668429
3. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet. 2003;361:117-24. Retraction in. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T, Lancet 2009 374 1226 10.1016/S0140-6736(09)61768-2 19819378
4. ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsärinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S, Lancet 2008 372 547 553 10.1016/S0140-6736(08) 61236-2 18707986
5. Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents. Esnault VL, Ekhlas A, Delcroix C, Moutel MG, Nguyen JM, J Am Soc Nephrol 2005 16 474 481 10.1681/ASN.2004060505 15615822 (Pubitemid 41725144)
6. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. Vogt L, Waanders F, Boomsma F, de Zeeuw D, Navis G, J Am Soc Nephrol 2008 19 999 1007 10.1681/ASN.2007060693 18272844
7. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. de Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, Parving HH, Pritchett Y, Remuzzi G, Ritz E, Andress D, Lancet 2010 376 1543 1551 10.1016/S0140-6736(10)61032-X 21055801
8. Renal structure and function in rats after suprapharmacologic doses of quinapril, an angiotensin-converting enzyme inhibitor. MacDonald JR, Susick RL, Pegg DG, Dominick MA, J Cardiovasc Pharmacol 1992 19 282 289 10.1097/00005344-199202000-00017 1376798
9. The juxtaglomerular apparatus in young type-1 diabetic patients with microalbuminuria, Effect of antihypertensive treatment. Gulmann C, Osterby R, Bangstad HJ, Rudberg S, Virchows Arch 2001 438 618 623 10.1007/s004280100396 11469695 (Pubitemid 32662382)
10. Calcineurin inhibitor toxicity in renal allografts: morphologic clues from protocol biopsies. Sharma A, Jain S, Gupta R, Guleria S, Agarwal S, Dinda A, Indian J Pathol Microbiol 2010 53 651 657 10.4103/0377-4929.72015 21045386
11. Renal juxtaglomerular apparatus hyperplasia. Troxell ML, Scandling JD, Sibley RK, Nephrol Dial Transplant 2005 20 2282 2283 10.1093/ndt/gfh883 15941848 (Pubitemid 41510114)
12. Effects of chronic volume expansion and enalapril on chronic cyclosporine nephropathy. Gillum DM, Truong L, Am J Physiol 1990 258 4 Pt 2 934 F939 2184676
13. Foetal kidney maldevelopment in maternal use of angiotensin II type I receptor antagonists. Dakha-Dahmane F, Levy-Beff E, Jugie M, Lenclen R, Pediatr Nephrol 2006 21 729 732 10.1007/s00467-006-0070-1 16565869
14. Diabetic complications: a role for the prorenin-(pro)renin receptor-TGF-beta1 axis? van der Heuvel M, Batenburg WW, Danser AH, Mol Cell Endocrinol 2009 302 213 218 10.1016/j.mce.2008.09.010 18840499
15. Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Kelly DJ, Zhang Y, Moe G, Naik G, Gilbert RE, Diabetologia 2007 50 2398 2404 10.1007/s00125-007-0795-9 17828524 (Pubitemid 47512400)
16. Vitamin D: a new hope for chronic kidney disease? Li M, Batuman V, Kidney Int 2009 76 1219 1221 10.1038/ki.2009.390 19946310
17. Battle against the renin-angiotensin system: help from an unexpected party. Müller D, Müller DN, Nephrol Dial Transplant 2009 24 1110 1112 19176687
18. Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Zhang Z, Zhang Y, Ning G, Deb DK, Kong J, Li YC, Proc Natl Acad Sci U S A 2008 105 15896 15901 10.1073/pnas.0803751105 18838678
19. Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. Freundlich M, Quiroz Y, Zhang Z, Zhang Y, Bravo Y, Weisinger JR, Li YC, Rodriguez-Iturbe B, Kidney Int 2008 74 1394 1402 10.1038/ki.2008.408 18813285
20. Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy. Sanchez-Nĩo MD, Sanz AB, Carrasco S, Saleem MA, Mathieson PW, Valdivielso JM, Ruiz-Ortega M, Egido J, Ortiz A, Nephrol Dial Transplant 2011 26 1797 1802 10.1093/ndt/gfq306 20504837
21. Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy. Sanchez-Nĩo MD, Bozic M, Cordoba-Lanus E, Valcheva P, Gracia O, Ibarz M, Fernandez E, Navarro-Gonzalez JF, Ortiz A, Valdivielso JM, Am J Physiol Renal Physiol 2011 Dec 14. [Epub ahead of print]